Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
16 studies found for:    Tysabri | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Tysabri Observational Program
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: natalizumab
2 Recruiting Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Condition: Graft Versus Host Disease
Interventions: Drug: Natalizumab;   Drug: Methylprednisolone
3 Recruiting Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS
Condition: Multiple Sclerosis
Intervention:
4 Recruiting Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Condition: Acute Graft Versus Host Disease
Interventions: Drug: natalizumab;   Drug: steroids
5 Recruiting Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Radiation: Diffusion Magnetic Resonance Imaging at 6 months
6 Recruiting Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Natalizumab
7 Not yet recruiting Inflammatory Response In Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Natalizumab;   Other: Placebo: normal saline
8 Recruiting Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Drug: natalizumab;   Drug: Placebo
9 Recruiting Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Procedure: biological samples and clinical data
10 Not yet recruiting Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis (MS)
Intervention: Drug: Alemtuzumab
11 Recruiting Methylprednisolone During the Switch Between Natalizumab and Fingolimod
Condition: Multiple Sclerosis
Interventions: Drug: Methylprednisolone;   Drug: Placebo;   Drug: natalizumab (NTZ);   Drug: fingolimob (FTY)
12 Recruiting Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Other: mitoxantrone - immunomodulator;   Other: natalizumab
13 Recruiting Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Daclizumab
14 Not yet recruiting Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab.
Condition: Relapsing Remitting Multiple Sclerosis
Intervention:
15 Recruiting Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
Condition: Multiple Sclerosis
Intervention:
16 Recruiting Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Tecfidera (BG12);   Drug: Gilenya;   Drug: Tysabri®;   Drug: Avonex/Betaseron/Copaxone/Rebif;   Procedure: Hematopoietic stem cell transplantation (HSCT)

Study has passed its completion date and status has not been verified in more than two years.